PlumX Metrics
Embed PlumX Metrics

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment

British Journal of Cancer, ISSN: 1532-1827, Vol: 120, Issue: 7, Page: 728-745
2019
  • 2
    Citations
  • 0
    Usage
  • 27
    Captures
  • 4
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    2
    • Citation Indexes
      2
  • Captures
    27
  • Mentions
    4
    • News Mentions
      4
      • 4

Most Recent News

How a new breast cancer biomarker could help patients identify best treatment options

According to the latest GLOBOCAN cancer database, New Zealand's breast cancer incidence rate is among the highest in the world. It affects one in nine women in their lifetime and accounts for almost half of all cancers for women in New Zealand.

Article Description

Background: SHON nuclear expression (SHON-Nuc ) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT). Methods: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship with the clinical outcome of treatments were analysed. Results: As previously reported, SHON-Nuc in high risk/ERα patients was significantly associated with a 48% death risk reduction after exclusive adjuvant tamoxifen treatment compared with SHON-Nuc [HR (95% CI) = 0.52 (0.34–0.78), p = 0.002]. Meanwhile, in ERα patients treated with adjuvant ACT, SHON cytoplasmic expression (SHON-Cyto ) was significantly associated with a 50% death risk reduction compared with SHON-Cyto [HR (95% CI) = 0.50 (0.34–0.73), p = 0.0003]. Moreover, in patients received Neo-ACT, SHON-Nuc or SHON-Cyto was associated with an increased pathological complete response (pCR) compared with SHON-Nuc [21 vs 4%; OR (95% CI) = 5.88 (1.28–27.03), p = 0.012], or SHON-Cyto [20.5 vs. 4.5%; OR (95% CI) = 5.43 (1.18–25.03), p = 0.017], respectively. After receiving Neo-ACT, patients with SHON-Nuc had a significantly lower distant relapse risk compared to those with SHON-Nuc [HR (95% CI) = 0.41 (0.19–0.87), p = 0.038], whereas SHON-Cyto patients had a significantly higher distant relapse risk compared to SHON-Cyto patients [HR (95% CI) = 4.63 (1.05–20.39), p = 0.043]. Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto was independently associated with a higher risk of distant relapse after Neo-ACT and 5-year tamoxifen treatment [HR (95% CI) = 5.08 (1.13–44.52), p = 0.037]. The interaction term between ERα status and SHON-Nuc (p = 0.005), and between SHON-Nuc and tamoxifen therapy (p = 0.007), were both statistically significant. Conclusion: SHON-Nuce in tumours predicts response to tamoxifen in ERα BC while SHON-Cyto predicts response to ACT.

Bibliographic Details

Abdel-Fatah, Tarek M A; Broom, Reuben J; Lu, Jun; Moseley, Paul M; Huang, Baiqu; Li, Lili; Liu, Suling; Chen, Longxin; Ma, Runlin Z; Cao, Wenming; Wang, Xiaojia; Li, Yan; Perry, Jo K; Aleskandarany, Mohammed; Nolan, Christopher C; Rakha, Emad A; Lobie, Peter E; Chan, Stephen Y T; Ellis, Ian O; Hwang, Le-Ann; Lane, David P; Green, Andrew R; Liu, Dong-Xu

Springer Science and Business Media LLC

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know